Keytruda (Pembrolizumab) is used to treat certain types of cancers (skin cancer, non-small cell lung cancer). It works by changing the action of your own immune system, directing it to attack cancer cells. Keytruda (Pembrolizumab) belongs to a class of drugs known as monoclonal antibodies.
Keytruda (Pembrolizumab) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), Keytruda (Pembrolizumab) induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumours to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, Keytruda (Pembrolizumab) acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
The following side effects are common (occurring in greater than 30%) for patients taking Keytruda (Pembrolizumab):
These side effects are less common side effects (occurring in about 10-29%) of patients receiving Keytruda (Pembrolizumab):
Before using Keytruda (Pembrolizumab), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Keytruda (Pembrolizumab) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.